franklinbiotechnologydiscovery fund - hsbc

Franklin Templeton Investment Funds

Franklin Biotechnology Discovery

Fund

Sector Equity28.02.2022

Fund Fact Sheet

E-Mail Web

[email protected] www.franklintempleton.com.hk

This is a marketing communication. Please refer to the offering documents before making any final investment decisions.

For the source and calculation basis of Fund information, please refer to the *Explanatory Notes section.

Risk ConsiderationsFranklin Biotechnology Discovery Fund invests principally in equity securities issued by biotechnology companies in the U.S.

and other countries.The Fund is subject to market risk, equity risk, biotechnology, communication and technology sectors risk, concentration risk,

smaller and midsize companies risk, growth stocks risk and securities lending risk.Security lending transactions may involve the risk that the borrower may fail to return the securities lent out in a timely

manner and the value of the collateral may fall below the value of the securities lent out, which may result in a substantial lossto the Fund.The Fund may at its discretion pay dividends out of the capital or out of gross income of the Fund while paying all or part of

the Fund s fees and expenses out of the capital of the Fund, which results in effectively paying dividends out of capital.Payment of dividends out of capital amounts to a return or withdrawal of part of an investor s original investment or from anycapital gains attributable to that original investment. Any distributions involving payment of dividends out of the Fund s capital orpayment of dividends effectively out of the Fund s capital (as the case may be) may result in an immediate reduction of the netasset value per share.Investment involves risks which may result in loss of part or entire amount of your investment. Before you decide to invest,

you should make sure the intermediary has explained to you that the Fund is suitable to you. Investors should not only base onthis marketing material alone to make investment decisions.

Performance*

Past performance does not predict future returns.

Performance over 5 Years in Share Class Currency (%)

Franklin Biotechnology Discovery Fund A (acc) USD

70

90

110

130

150

Fund Overview

Base Currency for Fund USD

Total Net Assets (USD) 1.82 billion

Fund Inception Date 03.04.2000

Number of Issuers 93

Benchmark NASDAQ BiotechnologyIndex

Morningstar Category * Sector EquityBiotechnology

02/17 08/17 02/18 08/18 02/19 08/19 02/20 08/20 02/21 08/21 02/22

Summary of Investment Objective

The Fund aims to achieve capital appreciation byinvesting principally in equity securities of biotechnologycompanies and discovery research firms mainly located inthe US.

Performance in Share Class Currency (%)

Cumulative3 Mths YTD 1 Yr 3 Yrs 5 Yrs 10 Yrs Since Incept

A (acc) USD -13.13 -13.12 -29.20 2.47 5.27 158.76 223.70

Benchmark in USD -16.60 -15.49 -19.05 12.78 28.59 224.96 275.13

Fund Management*

Evan McCulloch, CFA: United States

Wendy Lam, PhD: United States

Akiva Felt: United States

Calendar Year Performance in Share Class Currency (%)

2021 2020 2019 2018 2017

A (acc) USD -17.36 27.52 33.53 -16.31 16.93Benchmark in USD -0.63 25.69 24.41 -9.32 21.06

Top Ten Holdings* (% of Total)

Issuer NameVERTEX PHARMACEUTICALS INC 7.52AMGEN INC 6.60REGENERON PHARMACEUTICALS INC 6.30GILEAD SCIENCES INC 5.20HORIZON THERAPEUTICS PLC 5.10ILLUMINA INC 4.51JAZZ PHARMACEUTICALS PLC 3.25BIOGEN INC 3.01PTC THERAPEUTICS INC 2.99ASCENDIS PHARMA A/S 2.92

Fund MeasuresP/E to Growth 1.25xHistorical 3 Yr Sales Growth 57.81%Estimated 3-5 Yr EPS Growth 4.76%Price to Earnings (12-moForward)

14.77x

Standard Deviation (5 Yrs) 21.63%

Asset Allocation*

%Equity 96.63Cash & Cash Equivalents 3.37

Offering Documents

Shareholder Letters

Franklin Biotechnology Discovery Fund 28.02.2022

For the source and calculation basis of Fund information, please refer to the *Explanatory Notes section.

© 2022. Franklin Templeton. All rights reserved. www.franklintempleton.com.hk

Share Class Information

Fees Dividends Fund Identifiers

Share Class Incept Date NAV TER (%)Max. SalesCharge (%)

Max. AnnualCharge* (%)

Max. Serv.Charge (%)

Last PaidDate

Last PaidAmount ISIN

A (acc) USD 03.04.2000 USD 32.37 1.82 5.00 1.50 N/A N/A N/A LU0109394709A (acc) HKD 26.02.2013 HKD 21.08 1.82 5.00 1.50 N/A N/A N/A LU0889565916B (acc) USD 03.04.2000 USD 24.45 3.12 N/A 1.75 1.06 N/A N/A LU0109394881

The charges are the fees the fund charges to investors to cover the costs of running the Fund. Additional costs, including transaction fees, will also be incurred. These costs are paid out by theFund, which will impact on the overall return of the Fund.Fund charges will be incurred in multiple currencies, meaning that payments may increase or decrease as a result of currency exchange fluctuations.

Composition of Fund*

Market Capitalisation Breakdown in USD % of Equity<2.0 Billion 17.462.0-5.0 Billion 18.515.0-10.0 Billion 11.8610.0-25.0 Billion 11.3625.0-50.0 Billion 3.11>50.0 Billion 37.10N/A 0.59

Important Information

Unless stated otherwise, all information is as of the publishing date of this document. Source: Franklin Templeton.Copyright © 2022. Franklin Templeton. All rights reserved.Franklin Templeton Investments (Asia) Limited and Legg Mason Asset Management Hong Kong Limited are the issuers of this document. This document is for information only and nothing contained herein constitutes investment advice. All charts, data, opinions, estimates and other information are provided as of the date of this document and may be subject to change without notice. This document is neither an offer nor solicitation to purchase shares of the fund. Investments involves risks, fund value may go up as well as down and past performance is not an indicator or a guarantee of future performance. The investment returns are calculated on NAV to NAV basis, taking into account of reinvestments and capital gain or loss. The investment returns are denominated in stated currency, which may be a foreign currency other than USD and HKD ( other foreign currency ). US/HK dollar-based investors are therefore exposed to fluctuations in the US/HK dollar / other foreign currency exchange rate. Please refer to the offering documents for further details, including the risk factors.Any share class with H1 in its name will attempt to hedge the currency risk between the base currency of the Fund and the currency of the share class, although there can be no guarantee that it will be successful in doing so. In some cases, investors may be subject to additional risks.In addition, a summary of investor rights is available from https://www.franklintempleton.com.hk/en-hk/about-us/summary-of-investor-rights.The fund(s)/ sub-fund(s) are notified for marketing in various regions under the UCITS Directive. The fund(s)/ sub-fund(s) can terminate such notifications for any share class and/or sub-fund at any time by using the process contained in Article 93a of the UCITS Directive.Distribution of this document may be restricted in certain jurisdictions. This document does not constitute the distribution of any information or the making of any offer or solicitation by anyone in any jurisdiction in which such distribution or offer is not authorized or to any person to whom it is unlawful to distribute such a report or make such an offer or solicitation. Any person coming into possession of this document should seek advice for details of, and observe, such restrictions (if any). This document has not been reviewed by the Securities and Futures Commission of Hong Kong.

Legg Mason Asset Management Hong Kong Limited is an indirect wholly owned subsidiary of Franklin Resources, Inc.For the avoidance of doubt, if you make a decision to invest, you will be buying units/shares in the Fund and will not be investing directly in the underlying assets of the Fund.

*Explanatory Notes

Performance: Performance information is based on the stated share class only, in Fund Currency, NAV to NAV, taking into account of dividend reinvestments and capital gain or loss.When performance for either the portfolio or its benchmark has been converted, different foreign exchange closing rates may be used between the portfolio and its benchmark.Morningstar Category : Copyright © Morningstar, Inc. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is provided for reference purposes only. Past performance is not an indicator or a guarantee of future performance.Fund Management: In the case of portfolio managers who are CFA Charterholders, CFA® and Chartered Financial Analyst® are trademarks owned by CFA Institute.Top 10 Holdings: These securities do not represent all of the securities purchased, sold or recommended for clients, and the reader should not assume that investment in the securities listed was or will be profitable. The portfolio manager for the Fund reserves the right to withhold release of information with respect to holdings that would otherwise be included in the top holdings list. Asset Allocation/Composition of Fund: Due to rounding, the sum of portfolio may not equal 100%.Fees: Maximum Annual Charge includes Management Fee and Maximum Maintenance Charge.

Product Key Facts

Franklin Templeton Investment Funds –

Franklin Biotechnology Discovery Fund

Issuer: Franklin Templeton Investments (Asia) Limited

Last updated: December 2021

• This statement provides you with key information about this product.

• This statement is a part of the offering document.

• You should not invest in this product based on this statement alone.

Quick facts

Management company: Franklin Templeton International

Services S.à r.l.

Investment manager(s): Franklin Advisers, Inc., United States

of America (internal delegation)

Depositary: J.P. Morgan Bank Luxembourg S.A.

Base currency: USD

Financial year end of this Fund: 30 June

Dealing frequency: Every Hong Kong Business Day

Minimum Investment: USD 1,000 [initial] and USD 500 [subsequent purchases] or equivalent

Ongoing charges over a year#: Class A (acc) HKD: 1.83%

Class A (acc) USD: 1.83%

Class B (acc) USD: 3.14% #The ongoing charges figures are based on the annual report for the year ended 30 June 2021. These figures may vary from year to year.

Dividend policy: Dividends, if declared, will be reinvested unless

indicated by you in the application form to be paid out. Subject to

any legal and regulatory requirements, the Fund may at its

discretion pay dividends out of the capital or out of gross income

of the Fund while charging / paying all or part of the Fund’s fees

and expenses to / out of the capital of the Fund, which results in

an increase in distributable income for the payment of dividends

by the Fund and therefore, the Fund may effectively pay dividends

out of capital. The Fund may amend such distribution policy

subject to the Securities and Futures Commission (“SFC”)’s prior

approval and by giving not less than one month’s prior notice to

investors. Any distributions involving payment of dividends out of

the Fund’s capital or payment of dividends effectively out of the

Fund’s capital (as the case may be) may result in an immediate

reduction of the net asset value per share.

What is this product?

This is a fund constituted in the form of a mutual fund. It is domiciled in Luxembourg and its home regulator is Commission de

Surveillance du Secteur Financier.

Investment Objective and Policy

Franklin Biotechnology Discovery Fund (the “Fund”) aims to increase the value of its investments over the medium to long term.

The Fund invests principally (that is, at least two-thirds of the Fund’s net assets) in:

• equity securities issued by biotechnology companies located in the U.S. and other countries

In exceptional market circumstances (such as extreme volatility) and on a temporary basis only, 100% of the Fund’s net assets may

be invested in liquid assets, with due regard to the principle of risk spreading.

Franklin Templeton Investment Funds - Franklin Biotechnology Discovery Fund 1


The Fund can invest on an ancillary basis in:

• higher-quality debt securities issued by corporate issuers

A biotechnology company is one that earns at least 50% of its profits from or is devoted to activities such as health care,

pharmaceuticals or agriculture. The Fund will usually invest more in the U.S. than in any other country.

For the purpose of generating additional capital or income or for reducing costs or risks, the Fund may engage in securities lending

transactions for up to 50% of its net assets, in a manner that is consistent with its investment policy. For the avoidance of doubt, any

securities lending will be an ancillary activity of the Fund only.

Use of derivatives / investment in derivatives

The Fund’s net derivative exposure may be up to 50% of the Fund’s net asset value.

What are the key risks?

Investment involves risks. Please refer to the offering document for details including the risk factors.

• Market risk: The market values of securities owned by the Fund will tend to go up or down, sometimes rapidly or

unpredictably, due to factors affecting individual issuers, particular industries or sectors within securities markets, or because of

general market conditions. During a general downturn in the securities markets, multiple asset classes (including different

sectors of the same asset class) may decline in value at the same time. Similarly, when markets perform well, there can be no

assurance that securities held by the Fund will participate in the advance. Because the securities the Fund holds fluctuate in

price in this manner, the Fund’s value may go down as well as up and investors may be adversely affected.

• Equity risk: Equity and equity-linked securities are subject to significant price movements due to various economic, political,

market and issuer-specific factors. Such changes may adversely affect the value of equities regardless of issuer-specific

performance. Additionally, different industries, financial markets and securities can react differently to these changes. Such

fluctuations of the Fund’s value are often exacerbated in the short-term. Financial markets trends (including feared or actual

failures in the banking system) may also cause large fluctuations in the prices of such securities. As a result, the Fund may be

adversely affected.

• Foreign currency risk: The Fund will typically invest to a significant degree in securities that are denominated in currencies

other than the base currency of the Fund, exposing its investments to changes in foreign exchange rates and the possibility of

exchange control regulations. Changes in currency exchange rates may adversely affect the value of the Fund, and also may

affect the income earned by the Fund and gains and losses realized by the Fund. Furthermore, the total return for a share

class that is denominated in a different currency (the “alternative currency”) from the base currency of the Fund may be

affected, either positively or negatively, by changes in the exchange rate between the Fund’s base currency and the alternative

currency.

• Liquidity risk: The Fund may not be able to easily sell securities due to adverse market conditions or reduced value or

creditworthiness of issuers in which it invests. The inability of the Fund to sell securities or positions may also impede the ability

of the Fund to meet redemption requests in a timely manner. Certain securities may also be illiquid due to limited trading

markets or contractual restrictions on their resale. Reduced liquidity due to these factors may have an adverse impact on the

net asset value of the Fund.

• Biotechnology, communication and technology sectors risk: Investment in the biotechnology, communication and

technology sectors may present greater risk and higher volatility than investment in a broader range of securities covering

different economic sectors. Companies in these sectors may be in their preliminary stage of development and therefore may

rely heavily on research development and may face intense competition which may have an adverse effect on profit margins

and such companies will have high uncertainty and volatility in price performance when compared to other economic sectors.

The value and performance of the Fund may be adversely affected as a result.


• Debt securities risk: The Fund is exposed to the credit/default risk of issuers of the debt securities that the Fund may invest

in. Investment in the Fund is subject to interest rate risk. The debt securities will generally increase in value when interest rates

fall and decrease in value when interest rates rise.

• Concentration risk: The Fund’s investments are concentrated in a single sector. The value of the Fund may be more volatile

than that of a fund having a more diverse portfolio of investments and may be more susceptible to adverse economic, political,

policy, foreign exchange, liquidity, tax, legal or regulatory events affecting the sector in which it invests.

• Smaller and midsize companies risk: Stocks of smaller- and mid-sized companies tend to be less liquid and more volatile to

adverse economic developments than larger, more recognized companies, particularly if such companies are in emerging

markets, which results in higher risk for the Fund. The value and performance of the Fund may be adversely affected as a

result.

• Growth stocks risk: Growth stocks can be more volatile and may be more expensive, relative to earnings, than the market in

general. The Fund may be adversely affected by the greater volatility of investments in such stocks.

• Dividend policy risk: The Fund’s dividend policy allows for payment of dividends out of capital or effectively out of capital.

Where this is done, it amounts to a return or withdrawal of part of an investor’s original investment or from any capital gains

attributable to that original investment. Any distributions involving payment of dividends out of the Fund’s capital or payment of

dividends effectively out of the Fund’s capital (as the case may be) may result in an immediate reduction of the net asset value

per share.

• Counterparty risk: The Fund may be exposed to the credit/default risks of its counterparties and the Fund/investors may be

adversely impacted.

• Securities lending risk: Securities lending transactions may involve the risk that the borrower may fail to return the securities

lent out in a timely manner and the value of the collateral may fall below the value of the securities lent out, which may result in

a substantial loss to the Fund.

• Derivative instruments risk: Derivative instruments involve cost, may be volatile, and may involve a leverage effect. A small

market movement may give rise to a proportionately larger impact, which may cause substantial loss to the Fund. Other risks

include counterparty/credit risk, liquidity risk, valuation risk, volatility risk and over-the-counter transaction risk. In adverse

situations, the Fund’s use of derivative instruments may become ineffective and the Fund may suffer significant losses.


How has the Fund performed?

• Past performance information is not indicative of future performance. Investors may not get back the full amount invested.

• The computation basis of the performance is based on the calendar year end, NAV-to-NAV, with dividends reinvested.

• These figures show by how much class A (acc) USD increased or decreased in value during the calendar year being shown.

Class A (acc) USD is the share class available in Hong Kong with the longest history in the Fund. Performance data has been

calculated in USD, including ongoing charges and excluding subscription fee and redemption fee you might have to pay.

• Fund launch date: 3 April 2000

• Class A (acc) USD launch date: 3 April 2000

• Effective 25 February 2021, NASDAQ Biotechnology Index was added as the benchmark of the Fund to adhere to European

disclosure rules regarding the use of benchmark.

Is there any guarantee?

This Fund does not have any guarantees. You may not get back the full amount of money you invest.


What are the fees and charges?

Charges which may be payable by you

You may have to pay the following fees when dealing in the shares of the Fund.

Class A Class B

Subscription fee (Initial sales charge) Up to 5.00% of the

subscription amount

N/A

Switching fee (Switching charge)* 1.00% of the value of the

shares being switched

N/A

Redemption fee (Redemption charge) N/A Up to 4.00%

Ongoing fees payable by the Fund

The following expenses will be paid out of the Fund. They affect you because they reduce the return you get on your investments.

Annual rate (as a % of the Fund’s net asset value)

Class A Class B

Management fee (annual management charge*^) 1.50% 1.75%

Depositary fee Up to 0.140% Up to 0.140%

Performance fee N/A N/A

Administration fee N/A N/A

Servicing charge N/A 1.06%

Registrar and Transfer, Corporate, Domiciliary and

Administrative Agent fee

Up to 0.2175 % Up to 0.2175%

Additional fixed amount per Shareholder account at each Class

level

Up to USD 30 per annum Up to USD 30 per annum

*The current fee level may be increased up to the maximum level permitted by the constitutive document of the Fund by giving one

month’s prior notice to the shareholders.

^ The annual management charge as set out in the Explanatory Memorandum comprises the investment management fee and the

maintenance charge, details of which are provided in the annual report of Franklin Templeton Investment Funds.

Other fees

You may have to pay other fees and charges when dealing in the shares of the Fund.


Additional Information

• You generally buy and redeem shares at the Fund’s next determined net asset value (NAV) after the Hong Kong

Representative, Franklin Templeton Investments (Asia) Limited, receives your request in good order on or before 4:00 p.m.

(Hong Kong time) being the dealing cut-off time. Certain intermediaries may impose an earlier dealing cut-off time.

• The net asset value of this Fund is calculated and the price of shares is published on each business day. Information about

prices is available online at www.franklintempleton.com.hk.

• The compositions of the dividends (i.e. the relative amounts paid out of (i) net distributable income and (ii) capital) for the last 12

months are made available by the Hong Kong Representative on request and are also available online at

www.franklintempleton.com.hk.

• Investors may obtain the past performance information of other share classes offered to Hong Kong investors from the Hong

Kong Representative’s website at www.franklintempleton.com.hk.

• Investors may obtain information on the intermediaries by calling the Hong Kong Representative at (852) 2877-7733 or visiting

the Hong Kong Representative’s website at www.franklintempleton.com.hk.

• The website mentioned above has not been reviewed by the SFC.

Important

If you are in doubt, you should seek professional advice.

The SFC takes no responsibility for the contents of this statement and makes no representation as to its accuracy or completeness.

http://www.franklintempleton.com.hk/




28.02.2022

[email protected] www.franklintempleton.com.hk

*

*

5 ( ) (%)

A

70

90

110

130

150

( ) 1.82

03.04.2000

93

*

02/17 08/17 02/18 08/18 02/19 08/19 02/20 08/20 02/21 08/21 02/22

( ) (%)

3 1 3 5 10

A -13.13 -13.12 -29.20 2.47 5.27 158.76 223.70

-16.60 -15.49 -19.05 12.78 28.59 224.96 275.13

*

Evan McCulloch, CFA:

Wendy Lam, PhD:

Akiva Felt:

( ) (%)

2021 2020 2019 2018 2017

A -17.36 27.52 33.53 -16.31 16.93-0.63 25.69 24.41 -9.32 21.06

* ( %)

VERTEX PHARMACEUTICALS INC 7.52AMGEN INC 6.60REGENERON PHARMACEUTICALS INC 6.30GILEAD SCIENCES INC 5.20HORIZON THERAPEUTICS PLC 5.10ILLUMINA INC 4.51JAZZ PHARMACEUTICALS PLC 3.25BIOGEN INC 3.01PTC THERAPEUTICS INC 2.99ASCENDIS PHARMA A/S 2.92

1.25x3 57.81%3 5 4.76%

12 14.77x(5 ) 21.63%

*

%96.633.37

(%) (%) * (%) (%) ISINA 03.04.2000 32.37 1.82 5.00 1.50 LU0109394709A 26.02.2013 21.08 1.82 5.00 1.50 LU0889565916B 03.04.2000 24.45 3.12 1.75 1.06 LU0109394881

28.02.2022

*

Copyright © 2022 www.franklintempleton.com.hk

*

( ) %<2.0 17.462.0-5.0 18.515.0-10.0 11.8610.0-25.0 11.3625.0-50.0 3.11>50.0 37.10

0.59

Copyright © 2022 ( )

H1 https://www.franklintempleton.com.hk/en-hk/about-us/summary-of-investor-rights

UCITS / / UCITS 93a /

( )Franklin Resources, Inc.

/

*

:

: Copyright © Morningstar, Inc. (1) Morningstar, Inc. (2) (3)

CFA® Chartered Financial Analyst® :

/ 100%

費用: 最高年費包含管理費及最高維持費。

姿斌雌涼碍踊

布利告燐釗父曇東雌嬉銀 –

布利告燐精分果欺森緑郁嬉銀

皃講刃？布利告燐釗父曇東雌〔亠秋〕湧個効嗣

• 凡碍踊汀僑凡嬉銀適叔踊雌涼．• 凡碍踊制錏啅丙倦適溢楓噴．• 醒尤喃憮凡碍踊咋東雌穴底．

雌涼娩觀

緩痢効嗣？ Franklin Templeton International Services S.à r.l.

東雌絛痢？Franklin Advisers, Inc.,柊圓〔乳楓尉濁〕

尊緩刃？J.P. Morgan Bank Luxembourg S.A.

嬉銀過弊？柊厳

坂星捻奴習訣入？6 倹 30 入

侯為瓶湊艇奴？戾呼鴻甲嘶曲入

塞偵東雌掛？1,000 柊厳 [受治]宮 500 柊厳 [存悟戾治禰酵]袷筒‣

繕捻絛擾政貝斯疲葎#:

A (令蚕) 甲厳？ 1.83%

A (令蚕) 柊厳？1.83%

B (令蚕) 柊厳？3.14% #絛擾政貝斯疲葎制混擅戰詞 2021 捻 6 倹 30 入適捻奴宝穀警蚕・戾捻錦夏膿湧曙斟堂．

破束星錯？菰束(韮湧)哉東雌・償樋革仮甥真醒豹殻宙凋迷．修図膚

拷忍価烹励宮烹貴踊泣仮・凡嬉銀夏司羊錫条槲裕凡嬉銀適雌凡袷

裕綯畋尿宙斯手菰束・導滋甥～徘凡嬉銀適雌凡宙起尿～斯夫凡嬉

銀適繕楓袷楓噴非羊宮貝斯・位遅凡嬉銀羊甥斯夫菰束適夏噴培畋

尿夋嘉・引今・凡嬉銀夏寞在丞徘雌凡宙斯夫菰束．絛譛喧宮棄過

侍無竿撮尉姻偐〔『譛竿偐』〕侍占斐旬宮陶蚊喉東雌車皃述埠庄

甥溢呼倹適侍占栂弛・凡嬉銀夏拾蹄骸筒破束星錯．忍価菰束噴破

弱慎宮裕凡嬉銀適雌凡宙斯手菰束袷寞在丞裕凡嬉銀適雌凡宙斯手

菰束〔詩古条狭自底〕・夏撞遅戾菰雌姿淅‣捉滋玄庄．

凡嬉銀制腎庠姿斌゛

凡嬉銀位午悴嬉銀恵鴫訴整・罪蘯浸塋整掠・寿 Commission de Surveillance du Secteur Financier 竿緩．

東雌勿漂宮星錯

布利告燐精分果欺森緑郁嬉銀〔“凡嬉銀、〕遅倫甥宙棄詞鳥棄寞舷東雌夋‣．

布利告燐釗父曇東雌嬉銀 - 布利告燐精分果欺森緑郁嬉銀 1

塞悟校森？ 2021 捻 12 倹


凡嬉銀守踊〔捉凡嬉銀塞庄参噴嚢弐適淅雌姿〕東雌甥？

• 柊圓宮存太圓科精分果欺効嗣皃講嚢菰評譛喧．

罪禿珠適志嬢条狭仮〔励韮桐奴琶堂〕宮但罪隣滋嬉租丞・凡嬉銀塞剛奪 100%適淅雌姿罪肱虜蕩蕗隱噴燦適幻息仮・夏東雌甥琉堂雌

姿．

罪募女適条狭仮・凡嬉銀夏東雌甥？

• 効嗣皃講毅洪皃講嚢閣剛蔀蘇再無譛喧．

精分果欺効嗣孜詞庄 50%適頴履儘辞券恒乞痢，藹曲袷蚤曲筒曲無適効嗣・袷詞庄對 50%適頴履東雌皃添骸筒曲無適効嗣．凡嬉銀罪柊圓

適東雌栂擾汰甥存太圓科．

異夋嘉掛害雌凡袷畋悦袷異香偵整凡袷蕗隱・凡嬉銀夏位膚拷存東雌星錯適法鴫徘侍譛喧尺逮侯為・塞剛夏奪存雌姿淅‣適 50%．異綿尊

義・忍価譛喧尺逮對喰咋異凡嬉銀適募女東雌滑堂．

荏羊洫精巷虞～東雌洫精巷虞

凡嬉銀適洫精巷虞蕗隱招拜淅掛夏奪詞凡嬉銀雌姿淅‣適 50%．

凡嬉銀湧唅叉守踊蕗隱゛

東雌慎宮蕗隱・醒雙援錏啅丙倦・僚塊蕗隱引蘇筒雌涼．

• 志嬢蕗隱？裕甥寿呼蔑皃講毅洪，譛喧志嬢乳禿底講曲袷絵蔑適引蘇袷溢販志狭曳驚・凡嬉銀曙次譛喧適志嬢儉‣夏哨夏跋・湧滋

校夏膿述舷朽属袷矛烹幼警適哨跋．疇譛喧志嬢埠渓汕・汰呼雌姿伶蔑〔報渇導溢雌姿伶蔑適埠導絵蔑〕適儉‣夏膿導滋仮跋．導

橄恥・疇志嬢豹舷遼孝・夜埠膿鋪譛凡嬉銀曙次湧適譛喧對寿悴．引異凡嬉銀次湧適譛喧儉殻位丞峻法鴫琶堂・凡嬉銀適儉‣偐丞

哨宮仮跋・夏膿尠東雌車湧埠履曳驚．

• 菰評蕗隱？菰評宮菰評湧闥適譛喧夏膿寿汰高絛濬，星璽，志嬢宮皃講毅洪糟闥適禿底引蘇曳驚自述舷叔醍儉殻斟堂．埠和皃講毅

洪適獸禿豹舷・骸筒斟堂夏尠菰評儉‣湧埠履適曳驚．今害・埠導適講曲，銀予志嬢宮譛喧偐引懈骸筒斟堂自湧埠導適超晴．凡嬉

銀儉‣適骸筒琶福汰甥箪棄乳嘉撃．銀予志嬢据征〔報渇有虜袷寞在倶講髟継室敕〕又湧夏膿側整譛喧儉殻醍福琶堂．凡嬉銀夏膿

引今寿蕩埠履曳驚．

• 害弊蕗隱？凡嬉銀栂擾醍領東雌甥位凡嬉銀宝儉過弊位害適存太過弊底‣適譛喧・夏膿例骸筒東雌招寿匳葎斟堂宮害匳緩姓貴励適

曳驚．害琡兢舷葎適琶堂夏膿尠凡嬉銀適儉‣洪整赴摸曳驚・又夏曳驚凡嬉銀贄涜適畋尿宮凡嬉銀適寞在履純舍蚓遜．今害・位埠

導甥凡嬉銀宝儉過弊適過弊〔『吧溢夏銭擘過弊』〕警‣適菰伋伶蔑適綯壊宝・夏膿引凡嬉銀宝儉過弊舍吧溢夏銭擘過弊嚢関適匳

葎斟堂自寿蕩牲摸袷赴摸曳驚．

• 琉堂政蕗隱？凡嬉銀夏膿裕甥志狭偵鳴袷儉‣仮跋袷存東雌嚢皃講毅洪適唇讌惠何・自二位述啅譛喧．凡嬉銀矛烹述啅譛喧袷次壮

又夏膿曳驚凡嬉銀宮滋游俗赭壊醒泣適膿倫．弱患譛喧又夏膿引侯為志嬢湧個袷拷訳個姓轎啅自罌傍琉堂政．裕骸筒引蘇淫遅適琉


堂政香偵夏膿尠凡嬉銀適雌姿淅‣湧埠遼適曳驚．

• 精分果欺，栂迅宮果欺絵蔑蕗隱？東雌甥精分果欺，栂迅宮果欺絵蔑・存蕗隱閣東雌甥噴佪埠導絛濬絵蔑汰趣伶形適譛喧異醍・自

琶福又閣醍．今筒絵蔑適効嗣夏膿凭甥皃添適暑每凱談・引今袷偐剛奴囲赶絹笈皃添宮摸隣桁廉適凶爰・剝夏膿尠邏在履純側整赴

摸曳驚・叶糟尠甥存太絛濬絵蔑・骸筒効嗣罪儉殻豹舷法摸尊罪剛奴埠覚底政宮琶堂政．凡嬉銀適儉‣宮豹舷夏膿引今寿蕩埠履曳

驚．

• 再無譛喧蕗隱？凡嬉銀招寿凡嬉銀夏膿東雌適再無譛喧適皃講毅洪適唇逮～医訳蕗隱．凡嬉銀適東雌招寿履葎蕗隱．溢販自限・履

葎仮跋滋・再無譛喧適儉қ偐丞哨・履葎丞哨滋息偐仮跋．

• 什宙蕗隱？凡嬉銀適東雌什宙甥喃溢講曲．糟疲虞湧校汰厳何東雌訴拷適嬉銀・凡嬉銀適儉‣夏膿偐閣異琶堂宮夏膿校為寿蕩曳驚

存曙東雌講曲適埠履絛濬，星璽，星錯，害匳，琉堂政，隻無，烹立袷竿緩侍倦曳驚．

• 尚形宮宙形効嗣蕗隱？糟尠貴妄閣醍，閣異刃術漆適効嗣・尚形宮宙形効嗣適菰評適琉堂政溢販閣偵・叶罪埠履絛濬皃添条狭仮閣

異琶堂・籾存制弱骸筒効嗣偉甥森郷志嬢・例凡嬉銀招寿閣剛蕗隱．凡嬉銀適儉‣宮豹舷夏膿引今寿蕩埠履曳驚．

• 夋鳥菰蕗隱？父勉儘絕・修晴髟志嬢疲閣・夋鳥菰夏膿閣異琶堂・叶糟尠存畋尿夏膿閣異更軌．東雌甥骸筒菰評適閣醍琶福夏膿尠

凡嬉銀湧埠履曳驚．

• 破束星錯蕗隱？凡嬉銀嚢破束星錯咽鋸裕雌凡宙斯手菰束袷寞在丞裕雌凡宙斯手菰束．僲弱韮今講侍・筒甥隊間袷手壊東雌車嚢楓

噴幻東雌汗高袷忍価歿乢甥幻東雌汗高適雌凡畋悦．忍価菰束噴破弱慎宮裕凡嬉銀適雌凡宙斯手菰束袷寞在丞裕凡嬉銀適雌凡宙斯

手菰束〔詩古条狭自底〕・夏撞遅戾菰雌姿淅‣捉滋玄庄．

• 侯為尠殊蕗隱？凡嬉銀夏膿招寿存侯為尠殊曙幄儘適唇逮～医訳蕗隱・宮夏膿尠凡嬉銀～東雌車湧埠履曳驚．

• 譛喧尺逮蕗隱？譛喧尺逮侯為袷偐慎宮尺逮刃夏膿矛烹宮滋歿間譛喧・位宮提横斌儉қ跋詞偵甥尺述譛喧儉қ適蕗隱・剝夏膿撞遅

凡嬉銀招寿叔醍遜室．

• 洫精巷虞蕗隱？洫精巷虞適東雌慎宮整凡・又夏膿閣琶堂・閉夏膿慎宮槎梏敕懈．閣尚適志嬢琶堂夏膿側整糟尠醍適曳驚・袷偐例

凡嬉銀招寿叔醍遜室．存太蕗隱報渇侯為尠殊～唇逮蕗隱，琉堂政蕗隱，佝‣蕗隱，琶堂政蕗隱宮嬢害侯為志嬢侯為蕗隱．罪埠履

適志狭仮・凡嬉銀司羊洫精巷虞夏膿偐側整室敕・引自例凡嬉銀木寿叔醍遜室．


凡嬉銀蚊押適曲責豹舷韮価゛

• 押責閉樋幼速入悟曲責豹舷適孜漂．東雌車巳筆膿手壊繕楓東雌凡銀．

• 嬉銀曲責豹舷位鍊捻迄適雌姿淅‣咋異疲閣嬉租・菰束偐滲尊哉咋東雌．

• 丞峻斃擅顱耳 A 〔令蚕〕柊厳伶菰伋綯‣罪湧闥鍊捻乳適哨跋福奴．A〔令蚕〕柊厳伶菰伋制凡嬉銀甥鴻甲皃啅適菰伋伶蔑宙鍊四

塞揖休適．曲責豹舷位柊厳警蚕・疇宙帆栄述嬉銀適次纐非羊・辰埠報渇嬉銀夏膿喉革仮畋手適禰酵非宮赭壊非．

• 嬉銀皃講入: 2000 捻 4 倹 3 入

• A〔令蚕〕柊厳伶菰伋皃講入: 2000 捻 4 倹 3 入

• 裕 2021 捻 2 倹 25 入輝・嘉尿脳旨奪告精分果欺孜斃咋異凡嬉銀適嬉盾・位順朱歔秋湧闥嬉盾司羊適比婁貴息．

凡嬉銀湧庇汀僑鋪譛゛

凡嬉銀閉埠汀僑忍価鋪譛．革仮巳筆膿手壊東雌凡銀．


東雌凡嬉銀慎宮唅叉非羊宮畋非゛

革仮袷図纑夫適畋非

凡嬉銀菰伋侯為袷図纑夫位仮非羊．

A 伶菰伋 B 伶菰伋

禰酵非 (袷受治禰酵非羊) 塞剛異禰酵銀掛適 5.00% 埠溺羊

轎柑非 (袷轎柑非羊)* 轎柑菰伋適儉Ỻ適 1.00% 埠溺羊

赭壊非 (袷赭壊非羊) 埠溺羊塞剛 4.00%

凡嬉銀次纐纑夫適非羊

位仮畋非對徘凡嬉銀綯‣宙扠償・革仮適東雌壊宝對偐引自玄庄．

捻葎 (凡嬉銀雌姿淅Ỻ適俵噴斃)

A 伶菰伋 B 伶菰伋

緩痢非 (袷戾捻緩痢非*^) 1.50% 1.75%

尊緩非塞剛 0.140% 塞剛 0.140%

曲責豹舷非埠溺羊埠溺羊

講星非埠溺羊埠溺羊

腹無非埠溺羊 1.06%

賭起宮蚊顧，効嗣，顧脊宮講星大痢非塞剛 0.2175% 塞剛 0.2175%

拡呼伶蔑睡柄嚢菰伋次湧刃顧后嚢孤底銀掛非羊戾捻塞剛 30柊厳戾捻塞剛 30柊厳

*陶蚊喉菰伋次湧刃皃述溢呼倹適侍占栂弛・舷滋適畋非睡柄夏汀剛詞凡嬉銀嚢訴整丙倦曙咽鋸適塞剛睡柄．

^戾捻緩痢非・韮嬉銀絕迷藷曙剤・報渇東雌緩痢非宮胃次非・賞条剤甥布利告燐釗父曇東雌嬉銀適捻宝．

存太非羊

凡嬉銀菰伋侯為袷図纑夫存太非羊宮畋非．


存太雌迅

• 罪侯為戰氏滋関捉鴻甲滋関仮吾始滋袷嚢漸絛鴻甲大豹(捉布利告燐釗父曇東雌(亠秋)湧個効嗣)畋打適禰酵宮赭壊踊泣・溢販案邂悟

釟底適菰伋儉殻嫉講．楓噴宙解刃袷偐節底閣巣適侯為戰氏滋関．

• 凡嬉銀罪戾溢嘶曲入警蚕嚢雌姿淅‣宮効怖菰伋儉殻・夏陶蚊位仮蒙竝 www.franklintempleton.com.hk 穫手．

• 湧闥塞吟戎弐呼倹適菰束訴整〔捉徘〔i〕夏噴培淅畋尿宮〔ii〕雌凡宙噴破適糟尠斃掛〕・夏喉鴻甲大豹桜手・又夏陶蚊位仮蒙竝

www.franklintempleton.com.hk 穫手．

• 東雌車夏甥鴻甲大豹嚢蒙竝 www.franklintempleton.com.hk 手涜存太喉鴻甲東雌車錏啅適菰伋伶蔑嚢蚊押曲責雌涼．

• 東雌車夏遅吐 (852) 2877-7733 連酪鴻甲大豹袷瀛觀鴻甲大豹嚢蒙竝 www.franklintempleton.com.hk 手涜宙解刃適雌涼．

• 丞峻蒙竝閉巳異譛竿偐慎援．

叔踊汀耳

革仮韮湧義紋・懈賜誂尓曲易賢．

譛竿偐尠凡碍踊適乳揚閉埠招拜忍価跡忍・尠存盾覚政袷寛晴政又埠咋述忍価墜峻．